Comparative Pharmacology
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus TETRACHEL.
OXYTETRACYCLINE HYDROCHLORIDE vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic